• Home |
• Contacts |
• Links |
• Quality Standards |
• Instructions for Use |
• Careers

27 May 2004

NEW MEDIUM FOR PHARMACEUTICAL MEDIA FILL TRIALS

Microbiology specialists, Oxoid Limited, have launched gamma-irradiated, Cold Filterable Tryptone Soya Broth (CM1065) – a highly nutritious general purpose medium which is ideal for microbiological Media Fill Trials (MFT) in the pharmaceutical industry.

Dehydrated Cold Filterable Tryptone Soya Broth (TSB) can be substituted for the powdered components that go into making aqueous drug products. After carrying out MFT, including the filter-sterilisation process, the medium is incubated for the recovery of contaminating bacteria, yeasts and moulds¹. This provides an index of the level of microbiological contamination occurring in aseptic manufacture and can be used to identify problems in contamination control.

The components of Oxoid Cold Filterable TSB have been specially screened and selected to ensure a highly filterable solution. Each batch will have a known V cap (minimum 2,800 litres/m² ) tested using three different filter types (0.2 µm pore size): PVDF, PES and nylon. This allows the maximum filterable volume to be calculated before starting a MFT.

Oxoid Cold Filterable TSB may also be used to test aseptic production processes for solid presentations by adding the medium as a sterile liquid downstream of processing a placebo.

Gamma-irradiation of the medium ensures that it is free from all yeasts, moulds and bacteria, including bacterial spores and mycoplasmas , prior to use.

The Oxoid Cold Filterable TSB formulation conforms to that stated for MFT in the European², British³, US⁴ and Japanese⁵ Pharmacopoeias.

For further information, download the product datasheet in PDF format, or go to the product entry page on the web site. Alternatively, speak to your local Oxoid representative for further details.

References:

1. Oxoid Manual 8^th Edition, 1998, p2-208.
2. European Pharmacopoeia 4^th Edition 2002.
3. British Pharmacopoeia 2003.
4. US pharmacopoeia 27 NF22 2004.
5. Japanese Pharmacopoeia XIV 2001.